The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Update of the guidelines for lupus anticoagulant detection
Open accessAbstract
One of the conclusions of the subcommittee meeting on Lupus Anticoagulant/Phospholipid dependent antibodies, held in Geneva on 2007, was the need to update the guidelines on Lupus Anticoagulant (LA) detection. Particular emphasis was given to several aspects discussed in this official communication. A new paragraph is dedicated to the patient selection, and aims to minimize inappropriate requests for LA testing. Modalities for blood collection and processing are fully delineated and the choice of tests is limited to dRVVT and a sensitive aPTT. Calculation of cut-off values for each diagnostic step are clearly stated. A final paragraph reports the interpretation of the results in general and in particular situations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, persistently positive LAC and/or moderate/high Sapporo criteria aPL Abs (aCL IgG or IGM, or anti-b2GPI IgG or IgM) (10) were associated with HCQ use, OR 0.24 (0.06, 0.94), p=0.04”
From Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus (2013) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last update of the guidelines for LA detection by the International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (ISTH-SSC) in 2009 12 has proven useful in achieving greater uniformity in performance and interpretation of LA testing.”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, on other points, including testing in patients on anticoagulation, cutoff values, and calculation and interpretation of results, there was uncertainty or lack of agreement.12,15”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For samples from patients with no other causes of clotting time prolongation and LA assay confirmatory test results within reference intervals, the increasingly popular paradigm of integrated testing is sufficient to detect the presence of LA without performing the mixing test at all.6, 7, 8, 9, 26, 27, 28, 31, 33, 34”
From Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mixing test is mainly to discriminate between the presence of an inhibitor and coagulation factor deficiencies such as those occurring in patients on conventional oral anticoagulants/vitamin K antagonists (VKA).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines recommend mixing tests are interpreted with either a mixing test specific cut‐off (MTC) or the index of circulating anticoagulant (ICA).”
The cited source says what the claim attributes to it.
In the citing paper
“There is no single test to detect all LA1, 6, 7, 8 and guidelines recommend performance of two different tests that represent different assay principles, the diluted Russell's viper venom time (dRVVT) and a LA‐sensitive activated partial thromboplastin time (APTT).6, 7, 8”
The cited source says what the claim attributes to it.
In the citing paper
“LA positivity was determined following the Scientific and Standardization Committee (SSC)/International Society on Thrombosis and Hemostasis (ISTH) recommendations at the time of testing.11,13”
From Lupus anticoagulant test persistence over time and its associations with future thrombotic events (2022) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“The lupus anticoagulant assay (LA) followed international guidelines for the performance of this functional assay (54).”
From Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA (2019) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“According to ISTH/SSC (1) and CLSI (2) guidelines LAC identification should include three steps: screening for prolongation in a phospholipid-sensitive test, mixing with normal plasma to identify failure to correct and confirmation through result shortening in a phospholipid-rich test, (though in slightly different priority with CLSI).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Results were expressed as normalized ratios and interpreted according to in-house calculated cut-off values calculated with the 99th percentile (1).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Testing patients during VKA or other anticoagulant therapy for LAC remains a contentious issue and has been discouraged by official guidelines (1, 2) because of interpretational problems affecting the mixing test (8-10).”
From Mixing studies in lupus anticoagulant testing are required at least in some type of samples (2015) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Because there is no single assay sensitive to all LA antibodies, at least 2 coagulation tests based on different assay principles are recommended for LA detection [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Various interpretation indices, including percentage of correction (%Correct), screen-to-confirm ratio (SCR), and normalized SCR (NSCR), are suggested to determine the presence of LA in these phospholipid-dependent assays [[11], [12], [13]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Laboratory tests for LA detection comprise complex and multistep coagulation testing procedures, including screening, confirmatory, and mixing tests [[11], [12], [13]], and heterogeneity in these is an important cause of interlaboratory variation.”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“The diluted Russell’s viper venom time (dRVVT) assay is the first recommended test for detecting LA due to its high sensitivity and specificity [14], while the LA-sensitive activated partial thromboplastin time (aPTT) assay can be used as a secondary test [[11], [12], [13], [14]].”
From Comparison of different algorithms for lupus anticoagulant detection: a single-center experience (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“LAC was determined using the STA-R Evolution Coagulation Analyzer (Diagnostica Stago, Asnières-sur-Seine, France) according to ISTH guidelines 1 applying dilute Russell ' s viper venomtime (dRVVT Screen and dRVVT Confirm, Diagnostica Stago, Asnières-sur-Seine, France) and a sensitive activated partial thromboplastin time (aPTT) with silica as an activator (PTT-LA, Diagnostica Stago, Asnières-sur-”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“This study supports the dRVVT as the preferred assay to detect LAC. 1”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“and LAC was performed according to the ISTH guidelines. 1,34”
From Clinical Relevance of Isolated Lupus Anticoagulant Positivity in Patients with Thrombotic Antiphospholipid Syndrome (2021) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“LA was determined using two clotting assays as recommended by the 2009 International Society on Thrombosis and Haemostasis (ISTH) guidelines, 21 which were applicable at the time of the study: APTT by Diagnostica Stago and dRVVT by HYPHEN BioMed. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“However, the samples were analyzed before the publication of these new guidelines and therefore interpreted according to the guidelines that were applicable at this time. 21”
From Single or triple positivity for antiphospholipid antibodies in “carriers” or symptomatic patients: Untangling the knot (2021) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The majority of survey participants indicated that the number should be at least 40, which seems reasonable to guarantee an overall normal clotting factor activity. 12”
From Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis (2020) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MIYAKIS, S., LOCKSHIN, M. D., ATSUMI, T., BRANCH, D. W., BREY, R. L., CERVERA, R., DERKSEN, R. H. W. M., DE GROOT, P. G., KOIKE, T., MERONI, P. L., et al. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01753.x · Cited by 7,203
Self-citationBrandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Brandt, J. T., Triplett, D. A., Alving, B., & Scharrer, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649901 · Cited by 993
Rand, J. H., Wu, X.-X., Quinn, A. S., Chen, P. P., Hathcock, J. J., & Taatjes, D. J. (2008) · Blood · doi:10.1182/blood-2008-03-144204 · Cited by 215
Self-citationDetection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity
Rosner, E., Pauzner, R., Lusky, A., Modan, M., & Many, A. (1987) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651083 · Cited by 188
Galli, M., Finazzi, G., Bevers, E. M., & Barbui, T. (1995) · Blood · doi:10.1182/blood.v86.2.617.bloodjournal862617 · Cited by 146
Self-citationA Hexagonal (II) Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Identification
Triplett, D. A., Barna, L. K., & Unger, G. A. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649671 · Cited by 132
The Textarin/Ecarin Ratio: A Confirmatory Test for Lupus Anticoagulants
Triplett, D. A., Stocker, K. F., Unger, G. A., & Barna, L. K. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649701 · Cited by 110
Jennings, I., Kitchen, S., Woods, T. A. L., Preston, F. E., & Greaves, M. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656080 · Cited by 103
Meijer, P., Vermylen, J., & Arnout, J. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614601 · Cited by 96
Cited by
Sorted by citations
Items 101–200 of 1,001
Canaud, G., Bienaimé, F., Noël, L., Royal, V., Alyanakian, M., Dautzenberg, M., Rabant, M., Posson, J., Thervet, É., Anglicheau, D., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03233.x · Cited by 78
Orellana, D., & Kershaw, G. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0033-1336832 · Cited by 76
Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances
Vandevelde, A., & Devreese, K. M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082164 · Cited by 76
Pregnolato, F., Gerosa, M., Raimondo, M. G., Comerio, C., Bartoli, F., Lonati, P. A., Borghi, M. O., Acaia, B., Ossola, M. W., Ferrazzi, E. M., et al. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa203 · Cited by 76
Standardization of antiphospholipid antibody assays. Where do we stand?
Devreese, K. (2012) · Lupus · doi:10.1177/0961203312439335 · Cited by 76
Cohen, H., Doré, C. J., Clawson, S., Hunt, B. J., Isenberg, D., Khamashta, M. A., & Muirhead, N. (2015) · Lupus · doi:10.1177/0961203315581207 · Cited by 75
Antiphospholipid syndrome: Laboratory testing and diagnostic strategies
Ortel, T. L. (2012) · American Journal of Hematology · doi:10.1002/ajh.23196 · Cited by 75
Self-citationFavaloro, E. J., & Wong, R. C. W. (2014) · Pathology · doi:10.1097/pat.0000000000000142 · Cited by 75
The JAK2 V617F mutation in patients with cerebral venous thrombosis
Passamonti, S. M., Biguzzi, E., Cazzola, M., Franchi, F., Gianniello, F., Bucciarelli, P., Pietra, D., Mannucci, P. M., & Martinelli, I. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04719.x · Cited by 75
Chighizola, C. B., Pregnolato, F., Andréoli, L., Bodio, C., Cesana, L., Comerio, C., Gerosa, M., Grossi, C., Kumar, R., Lazzaroni, M. G., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.02.002 · Cited by 78
Guidelines on the investigation and management of antiphospholipid syndrome
Arachchillage, D. J., Platton, S., Hickey, K. P., Chu, J., Pickering, M. C., Sommerville, P., MacCallum, P., & Breen, K. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19635 · Cited by 77
β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome
Tanimura, K., Jin, H., Suenaga, T., Morikami, S., Arase, N., Kishida, K., Hirayasu, K., Kohyama, M., Ebina, Y., Yasuda, S., et al. (2015) · Blood · doi:10.1182/blood-2014-08-593624 · Cited by 74
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.
Franchini, M., Castaman, G., Coppola, A., Santoro, C., Zanon, E., Minno, G. D., Morfini, M., Santagostino, E., & Rocino, A. (2015) · PubMed Central · doi:10.2450/2015.0141-15 · Cited by 74
Detection of lupus anticoagulant in the era of direct oral anticoagulants
Hoxha, A., Banzato, A., Ruffatti, A., & Pengo, V. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.12.010 · Cited by 74
Self-citationFavresse, J., Lardinois, B., Sabor, L., Devalet, B., Vandepapeliere, J., Braibant, M., Lessire, S., Chatelain, B., Jacqmin, H., Douxfils, J., et al. (2018) · TH Open · doi:10.1055/s-0038-1657785 · Cited by 73
Płazak, W., Gryga, K., Dziedzic‐Oleksy, H., Pająk, L. T., Konieczyńska, M., Podolec, P. S., & Musiał, J. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3402 · Cited by 73
Gebhart, J., Posch, F., Koder, S., Perkmann, T., Quehenberger, P., Zoghlami, C., Ay, C., & Pabinger, I. (2015) · Blood · doi:10.1182/blood-2014-11-611129 · Cited by 77
Chayoua, W., Kelchtermans, H., Moore, G. W., Musiał, J., Wahl, D., de Laat, B., & Devreese, K. M. J. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14261 · Cited by 71
Rivaroxaban and false positive lupus anticoagulant testing
Kaplan, Z., Butler, J., Malan, E., Gan, E., Tran, H., & Merriman, E. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-08-0511 · Cited by 71
Weingarz, L., Schwonberg, J., Schindewolf, M., Hecking, C., Wolf, Z., Erbe, M., Weber, A., Lindhoff‐Last, E., & Linnemann, B. (2013) · British Journal of Haematology · doi:10.1111/bjh.12575 · Cited by 70
Artoni, A., Abbattista, M., Bucciarelli, P., Gianniello, F., Scalambrino, E., Pappalardo, E. M., Peyvandi, F., & Martinelli, I. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617733039 · Cited by 70
Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?
Barbhaiya, M., & Erkan, D. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-010-0149-3 · Cited by 69
Use of direct oral anticoagulants in antiphospholipid syndrome
Cohen, H., Efthymiou, M., & Isenberg, D. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14017 · Cited by 69
de Moerloose, P., Reber, G., Musiał, J., & Arnout, J. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03857.x · Cited by 68
Self-citationPassamonti, S. M., Berardino, F. D., Bucciarelli, P., Berto, V., Artoni, A., Gianniello, F., Ambrosetti, U., Cesarani, A., Pappalardo, E. M., & Martinelli, I. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.01.001 · Cited by 68
Cattini, M. G., Bison, E., Pontara, E., Cheng, C., Denas, G., & Pengo, V. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14765 · Cited by 68
Self-citationFavaloro, E. J., Mohammed, S., Curnow, J., & Pasalic, L. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.008 · Cited by 67
Sciascia, S., Murru, V., Garcia-Fernandez, C., Sanna, G., Khamashta, M., & Bertolaccini, M. L. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0527 · Cited by 67
Obstetric antiphospholipid syndrome
Antovič, A., Sennström, M., Bremme, K. A., & Svenungsson, E. (2018) · Lupus Science & Medicine · doi:10.1136/lupus-2016-000197 · Cited by 67
Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder
D’Ippolito, S., Meroni, P. L., Koike, T., Veglia, M., Scambia, G., & Simone, N. D. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.05.004 · Cited by 64
Mixing studies in lupus anticoagulant testing are required at least in some type of samples
Devreese, K. M. J., & de Laat, B. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13020 · Cited by 63
Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
Favaloro, E. J., & Pasalic, L. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12676 · Cited by 62
Mankee, A., Petri, M., & Magder, L. S. (2015) · Lupus Science & Medicine · doi:10.1136/lupus-2015-000095 · Cited by 63
Zuily, S., Domingues, V., Selton‐Suty, C., Eschwège, V., Bertoletti, L., Chaouat, A., Chabot, F., Regnault, V., Horn, E. M., Erkan, D., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.04.003 · Cited by 62
Bonar, R. A., Lippi, G., & Favaloro, E. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7196-1_1 · Cited by 61
Comellas-Kirkerup, L., Hernández‐Molina, G., & Cabral, A. R. (2010) · Blood · doi:10.1182/blood-2010-05-283507 · Cited by 61
Stępień, K., Nowak, K. W., Wypasek, E., Zalewski, J., & Undas, A. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.05.037 · Cited by 61
Arachchillage, D. J., Mackie, I. J., Efthymiou, M., Isenberg, D. A., Machin, S. J., & Cohen, H. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12917 · Cited by 60
Mani, H., Hesse, C., Stratmann, G., & Lindhoff-Last, E. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-04-0228 · Cited by 60
Radin, M., Schreiber, K. I., Costanzo, P., Cecchi, I., Roccatello, D., Baldovino, S., Bazzan, M., Cuadrado, M. J., & Sciascia, S. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.155 · Cited by 60
Ünlü, O., Erkan, D., Barbhaiya, M., ANDRADE, D. C. O. D., Nascimento, I. S., Rosa, R. F., Banzato, A., Pengo, V., Ugarte, A., Gerosa, M., et al. (2018) · Arthritis Care & Research · doi:10.1002/acr.23584 · Cited by 60
Self-citationAutoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA
Becker, Y., Marcoux, G., Allaeys, I., Julien, A.-S., Loignon, R.-C., Benk-Fortin, H., Rollet-Labelle, E., Rauch, J., Fortin, P. R., & Boilard, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01026 · Cited by 59
KUMANO, O., IEKO, M., NAITO, S., YOSHIDA, M., & TAKAHASHI, N. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04906.x · Cited by 59
Lupus Anticoagulant Identifies Two Distinct Groups of Patients with Different Antibody Patterns
Pengo, V., Del Ross, T., Ruffatti, A., Bison, E., Cattini, M. G., Pontara, E., Testa, S., Legnani, C., Pozzi, N., Peterle, D., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.11.003 · Cited by 59
Self-citationHisada, R., Kato, M., Sugawara, E., Fujieda, Y., Oku, K., Bohgaki, T., Amengual, O., Yasuda, S., & Atsumi, T. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13763 · Cited by 59
The Laboratory and the New Oral Anticoagulants
Tripodi, A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.189704 · Cited by 58
Self-citationColoma Bazán, E., Donate López, C., Moreno Lozano, P., Cervera, R., & Espinosa, G. (2013) · Immunologic Research · doi:10.1007/s12026-013-8407-x · Cited by 57
Hoxha, A., Mattia, E., Tonello, M., Grava, C., Pengo, V., & Ruffatti, A. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0638 · Cited by 57
Self-citationIncreased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac‐1
Sule, G. J., Kelley, W. J., Gockman, K., Yalavarthi, S., Vreede, A. P., Banka, A. L., Bockenstedt, P. L., Eniola‐Adefeso, O., & Knight, J. S. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41057 · Cited by 57
Bazzan, M., Vaccarino, A., Stella, S., Sciascia, S., Montaruli, B., Bertero, M. T., Carignola, R., Roccatello, D., & for the Piedmont APS Consortium (2016) · Lupus · doi:10.1177/0961203315617538 · Cited by 56
Lupus anticoagulant is frequent in patients with Covid‐19: Response to reply
Harzallah, I., Debliquis, A. P., & Drénou, B. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14980 · Cited by 56
Hoecke, F. V., Persijn, L., Decavele, A.-S. C., & Devreese, K. M. J. (2012) · International Journal of Laboratory Hematology · doi:10.1111/j.1751-553x.2012.01448.x · Cited by 56
Antiphospholipid antibodies: Evaluation of the thrombotic risk
Devreese, K. M. J. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.08.270 · Cited by 56
Fritsma, G. A., Dembitzer, F. R., Randhawa, A., Marques, M. B., Cott, E. M. V., Funk, D. M. A., & Peerschke, E. I. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcp3j1zkybfqxjm · Cited by 56
Sciascia, S., Cuadrado, M. J., Sanna, G., Murru, V., Roccatello, D., Khamashta, M. A., & Bertolaccini, M. L. (2014) · Arthritis Care & Research · doi:10.1002/acr.22388 · Cited by 55
ISTH guidelines on Lupus Anticoagulant testing
Pengo, V. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.08.283 · Cited by 55
Self-citationRiancho‐Zarrabeitia, L., Martínez-Taboada, V. M., Rúa‐Figueroa, Í., Sánchez‐Alonso, F., Galindo-Izquierdo, M., Ovalles-Bonilla, J. G., Olivé, A., Fernández‐Nebro, A., Alén, J. C., Menor-Almagro, R., et al. (2020) · Lupus · doi:10.1177/0961203320950477 · Cited by 55
Ruffatti, A., Favarò, M., Hoxha, A., Zambon, A., Marson, P., Ross, T. D., Calligaro, A., Tonello, M., & Nardelli, G. B. (2016) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2016.03.004 · Cited by 55
Risk factors for arterial thrombosis in antiphospholipid syndrome
Matyja‐Bednarczyk, A., Swadźba, J., Iwaniec, T., Sanak, M., Dziedzina, S., Ćmiel, A., & Musiał, J. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.11.012 · Cited by 54
Chauleur, C., Galanaud, J. ‐., Alonso, S., Cochery-Nouvellon, É., Balducchi, J.-P., Marès, P., Fabbro-Péray, P., & Gris, J. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03747.x · Cited by 54
Endothelial and platelet microparticles in patients with antiphospholipid antibodies
Breen, K. A., Sanchez, K., Kirkman, N., Seed, P. T., Parmar, K., Moore, G. W., & Hunt, B. J. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.027 · Cited by 54
Lupus-anticoagulant testing at NOAC trough levels
Ratzinger, F., Lang, M., Belik, S., Jilma‐Stohlawetz, P., Schmetterer, K. G., Haslacher, H., Perkmann, T., & Quehenberger, P. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-02-0081 · Cited by 54
Persijn, L., Decavele, A.-S., Schouwers, S., & Devreese, K. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.04.004 · Cited by 53
Lupus Anticoagulant Testing: Performance and Practices by North American Clinical Laboratories
Dembitzer, F. R., Ledford Kraemer, M. R., Meijer, P., & Peerschke, E. I. B. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcp4spplg5xvixf · Cited by 53
Favaloro, E. J. (2020) · American Journal of Hematology · doi:10.1002/ajh.25669 · Cited by 53
The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases
Son, M., Wypasek, E., Celińska‐Löwenhoff, M., & Undas, A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.01.028 · Cited by 53
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome
Malec, K., Góralczyk, T., & Undas, A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.12.009 · Cited by 53
Nakamura, H., Oku, K., Amengual, O., Ohmura, K., Fujieda, Y., Kato, M., Bohgaki, T., Yasuda, S., & Atsumi, T. (2017) · Arthritis Care & Research · doi:10.1002/acr.23310 · Cited by 54
Favaloro, E. J., Gilmore, G., Arunachalam, S., Mohammed, S., & Baker, R. I. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.013 · Cited by 53
Preanalytical Issues in Hemostasis and Thrombosis Testing
Lippi, G., & Favaloro, E. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7196-1_2 · Cited by 53
Venous and Arterial Thrombotic Events in Systemic Lupus Erythematosus
Hinojosa‐Azaola, A., Romero‐Díaz, J., Vargas-Ruíz, Á. G., Núñez‐Álvarez, C. A., Cicero‐Casarrubias, A., Ocampo-Torres, M. C., & Sánchez‐Guerrero, J. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150506 · Cited by 52
The Role of Complement Inhibition in Thrombotic Angiopathies and Antiphospholipid Syndrome
Erkan, D., & Salmon, J. E. (2016) · Turkish Journal of Hematology · doi:10.4274/tjh.2015.0197 · Cited by 52
The antiphospholipid syndrome: still an enigma
Chaturvedi, S., & McCrae, K. R. (2015) · Hematology · doi:10.1182/asheducation-2015.1.53 · Cited by 51
Value of repeat biopsy in lupus nephritis flares
Greloni, G. C., Scolnik, M., Marín, J., Lancioni, E., Quiroz, C. M., Zacariaz, J., Niveyro, P. X. D. L. I., Christiansen, S., Pierangelo, M. A., Varela, C. F., et al. (2014) · Lupus Science & Medicine · doi:10.1136/lupus-2013-000004 · Cited by 52
Vandevelde, A., Chayouâ, W., de Laat, B., Moore, G. W., Musiał, J., Zuily, S., Wahl, D. G., & Devreese, K. M. J. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15785 · Cited by 52
The Lupus Anticoagulant Paradox
Molhoek, J. E., de Groot, P. G., & Urbanus, R. T. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1606190 · Cited by 50
Miranda, S., Park, J., Gal, G. L., Piran, S., Kherani, S., Rodger, M. A., & Delluc, A. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14720 · Cited by 53
Antiphospholipid syndrome: state of the art on clinical practice guidelines
Limper, M., Scirè, C. A., Talarico, R., Amoura, Z., Avčin, T., Basile, M., Burmester, G. R., Carli, L., Cervera, R., Costedoat-Chalumeau, N., et al. (2018) · RMD Open · doi:10.1136/rmdopen-2018-000785 · Cited by 50
Favaloro, E., Bonar, R., & Marsden, K. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1311993 · Cited by 49
de Laat, B., Derksen, R. H. W. M., Reber, G., Musiał, J., Swadźba, J., Božič, B., Čučnik, S., Regnault, V., Forastiero, R. R., Woodhams, B. J., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04068.x · Cited by 49
Self-citationThe lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic
Clark, C. A., Davidovits, J., Spitzer, K. A., & Laskin, C. A. (2013) · Blood · doi:10.1182/blood-2013-02-485839 · Cited by 49
Cohen, H., Mackie, I. J., & Devreese, K. M. J. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14560 · Cited by 48
Ferrari, É., Sartre, B., Squara, F., Contenti, J., Occelli, C., Lemoël, F., Levraut, J., Doyen, D., Dellamonica, J., Mondain, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017773 · Cited by 48
Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
FAVALORO, E. J., BONAR, R., ZEBELJAN, D., KERSHAW, G., & MARSDEN, K. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04090.x · Cited by 48
Antiphospholipid antibodies — We are not quite there yet
Urbanus, R. T., & de Groot, P. G. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.12.001 · Cited by 48
Sciascia, S., Baldovino, S., Schreiber, K. I., Solfietti, L., Radin, M., Cuadrado, M. J., Menegatti, E., Erkan, D., & Roccatello, D. (2016) · Clinical and Molecular Allergy · doi:10.1186/s12948-016-0043-2 · Cited by 48
Gibbins, K. J., Tebo, A. E., Nielsen, S., & Branch, D. W. (2018) · Lupus · doi:10.1177/0961203318787035 · Cited by 48
Minno, M. N. D. D., Scalera, A., Tufano, A., Ambrosino, P., Bettiol, A., Silvestri, E., Emmi, G., & Prisco, D. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.09.010 · Cited by 48
De Kesel, P. M. M., & Devreese, K. M. J. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12264 · Cited by 47
Pengo, V., Ruffatti, A., Tonello, M., Hoxha, A., Bison, E., Denas, G., Padayattil Jose, S., Zoppellaro, G., Bracco, A., & Banzato, A. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.04.031 · Cited by 47
Self-citationReality Check on Antiphospholipid Antibodies in COVID‐19–Associated Coagulopathy
Gkrouzman, E., Barbhaiya, M., Erkan, D., & Lockshin, M. D. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41472 · Cited by 47
Patil, R., Ghosh, K., Satoskar, P. R., & Shetty, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081407 · Cited by 47
Association between red cell distribution width and risk of venous thromboembolism
Bucciarelli, P., Maino, A., Felicetta, I., Abbattista, M., Passamonti, S. M., Artoni, A., & Martinelli, I. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.020 · Cited by 47
Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management
Radin, M., Lopes, M. R. U., Sciascia, S., & ANDRADE, D. C. O. D. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2017.12.006 · Cited by 47
Ząbczyk, M., Kopytek, M., Natorska, J., & Undas, A. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-1197 · Cited by 47
Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome
Devreese, K. M. J., Zuily, S., & Meroni, P. L. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100134 · Cited by 51
Effects of Direct Oral Anticoagulants on Lupus Anticoagulant Assays in a Real-Life Setting
Antovic, A., Norberg, E.-M., Berndtsson, M., Rasmuson, A., Malmström, R. E., Skeppholm, M., & Antovic, J. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0204 · Cited by 46
Sciascia, S., Radin, M., Cecchi, I., Rubini, E., Scotta, A. M., Rolla, R., Montaruli, B., Pergolini, P., Mengozzi, G., Muccini, E., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00376 · Cited by 46
Conti, F., Ceccarelli, F., Iaiani, G., Perricone, C., Giordano, A., Amori, L., Miranda, F., Massaro, L., Pacucci, V. A., Truglia, S., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1079-x · Cited by 45
Laboratory Diagnostics in Thrombophilia
Hart, C., & Linnemann, B. (2019) · Hämostaseologie · doi:10.1055/s-0039-1677840 · Cited by 49
Metadata
- Authors
- PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G.
- Affiliations
- University of Padua (IT)
- University of Milan (IT)
- University Hospital of Geneva (CH)
- Montefiore Medical Center (US)
- Duke Medical Center (US)
- Corresponding author
- PENGO, V.
- Venue
- Journal of Thrombosis and Haemostasis
- Publisher
- Elsevier BV
- Published
- 2009-10
- Volume
- 7
- Issue
- 10
- Pages
- 1737-1740
- ISSN
- 1538-7836 (ISSN-L)
- OpenAlex
- W2069797332
- Cited by
- 1,197
- References
- 21
- Citations by year
- 2026: 20 · 2025: 32 · 2024: 53 · 2023: 55 · 2022: 65 · 2021: 89 · 2020: 99 · 2019: 101 · 2018: 88 · 2017: 82 · 2016: 80 · 2015: 75 · 2014: 81 · 2013: 69 · 2012: 82
- FWCI
- 48.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
- Keywords
- lupus anticoagulant, patient selection, activated partial thromboplastin time, cut-off values, interpretation of results, diagnostic guidelines
- MeSH terms
- Anticoagulants, Blood Coagulation, Blood Specimen Collection, Female, Humans, Indicators and Reagents, Male, Partial Thromboplastin Time, Phospholipids, Pregnancy, Pregnancy Complications, Hematologic, Prothrombin Time, Specimen Handling, Vitamin K, Artifacts, Lupus Coagulation Inhibitor, Antiphospholipid Syndrome, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
